Spotlight On... Sun closing Ranbaxy plant in Ireland; U.K. finds fault with Alkem plant; Serbia seeks investment in Galenika; and more...

sun pharma building

Sun Pharmaceutical will lay off about 70 workers and close a plant in Ireland as it cuts back its manufacturing network following its buyout of Ranbaxy Laboratories last year. Sun had put the plant up for sale last year but was unable to find a buyer. According to the Irish Times, a company statement said the plant would close by the end of the year but the company intends to move some jobs to other facilities in its network. "The Cashel facility closure is being implemented as part of this plan to right size the company's global manufacturing activities," said a statement sent to the newspaper. "We expect to cease operations at Cashel by end of current calendar year." Story | More

> Indian drugmaker Alkem Laboratories says the U.K.'s inspectors noted 8 observations during an inspection of a plant in Taloja, Maharashtra. Report

> Indian drugmaker Makers Pharma says it will sell a plant in Thane. Report

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> Serbia is inviting bids for a 25% share in its debt-laden and money-losing pharma company, Galenika. Story

Read more on

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.